TSE:4536Pharmaceuticals
MHRA Approval of Ryjunea® Could Be a Game Changer for Santen Pharmaceutical (TSE:4536)
In the past week, Santen Pharmaceutical announced that the UK Medicines and Healthcare products Regulatory Agency (MHRA) approved Ryjunea® (low-dose atropine 0.1 mg/ml) as the first licensed treatment to slow the progression of myopia in children, following earlier European Commission approval and launches in Europe.
This milestone offers Santen a new opportunity to address the rising prevalence of childhood myopia in the UK and further strengthens its international presence in paediatric...